+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

POC Lipid Testing - Global Strategic Business Report

  • PDF Icon

    Report

  • 381 Pages
  • June 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5030761
The global market for POC Lipid Testing was estimated at US$647.0 Million in 2025 and is projected to reach US$844.0 Million by 2032, growing at a CAGR of 3.9% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global POC Lipid Testing  Market - Key Trends and Drivers Summarized

Instant Health Insights: The Role of POC Lipid Testing

Point-of-care (POC) lipid testing refers to the process of measuring lipid levels directly at the site of patient care, providing immediate results without the need for centralized laboratory facilities. This testing typically measures key lipid parameters, including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides, which are critical for assessing cardiovascular health. POC lipid testing devices often use small blood samples obtained through a finger prick. The blood is applied to a test strip or cassette, which is then analyzed by a portable device using methods such as colorimetric assays or biosensors. The rapid turnaround of results allows healthcare providers to make prompt clinical decisions, enhancing patient management and facilitating early intervention in cases of dyslipidemia and other lipid-related disorders.

How Is POC Lipid Testing Utilized in Clinical Practice?

In clinical practice, POC lipid testing plays a crucial role in both routine health assessments and the management of chronic conditions. Primary care physicians use these tests during regular check-ups to monitor patients` lipid levels, enabling the early detection of hyperlipidemia and other cardiovascular risk factors. For patients with known lipid disorders, POC testing provides a convenient way to track treatment efficacy and adjust medications as needed. In emergency settings, rapid lipid testing can aid in the risk stratification of patients presenting with acute coronary syndromes or other cardiovascular events. Furthermore, POC lipid testing is invaluable in remote and resource-limited settings where access to laboratory facilities may be restricted, ensuring that patients still receive essential diagnostic services. The immediacy and convenience of POC lipid testing make it an indispensable tool in modern healthcare, particularly in scenarios requiring swift clinical decisions.

What Are the Current Trends in POC Lipid Testing Technology?

The technology behind POC lipid testing is continually advancing, driven by the need for greater accuracy, ease of use, and integration with broader healthcare systems. One notable trend is the miniaturization and portability of testing devices, which are becoming increasingly compact and user-friendly, facilitating their use in various healthcare environments. Advances in biosensor technology are enhancing the sensitivity and specificity of these devices, ensuring more reliable results. Integration with digital health platforms is another significant trend, allowing for the automatic upload of test results to electronic health records (EHRs) and enabling remote monitoring and telemedicine applications. Additionally, there is growing interest in developing multi-analyte POC devices that can assess multiple health parameters simultaneously, providing a more comprehensive overview of a patient’s cardiovascular health. These innovations are making POC lipid testing more accessible, efficient, and informative, improving overall patient care and management.

What Factors Are Driving the Growth in the POC Lipid Testing Market?

The growth in the POC lipid testing market is driven by several factors, reflecting the increasing demand for rapid and reliable diagnostic tools. The rising prevalence of cardiovascular diseases and the global emphasis on preventive healthcare are significant drivers, as early detection and management of lipid disorders are critical for reducing cardiovascular risk. Technological advancements in POC testing devices, including improved accuracy, portability, and integration with digital health systems, are enhancing their adoption across various healthcare settings. The expanding use of telemedicine and remote patient monitoring, especially in response to the COVID-19 pandemic, is also boosting demand for POC lipid testing, as it supports ongoing patient care without the need for frequent in-person visits. Additionally, the growing focus on personalized medicine is encouraging the use of POC testing to provide tailored treatment plans based on real-time lipid level assessments. These factors collectively ensure robust growth in the POC lipid testing market, underscoring its vital role in modern healthcare and chronic disease management.

Report Scope

The report analyzes the POC Lipid Testing market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Offering (Instruments Offering, Consumables Offering); Indication (Lipid & Lipoprotein Disorder Indication, Atherosclerosis Indication, Liver & Renal Diseases Indication, Diabetes Mellitus Indication, Other Indications); End-Use (Hospitals End-Use, Clinics End-Use, Diagnostic Laboratories End-Use, Other End-Uses)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Instruments Offering segment, which is expected to reach US$550.2 Million by 2032 with a CAGR of a 4.7%. The Consumables Offering segment is also set to grow at 2.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $198.5 Million in 2025, and China, forecasted to grow at an impressive 7.6% CAGR to reach $213.0 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global POC Lipid Testing Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global POC Lipid Testing Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global POC Lipid Testing Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as A. Menarini Industrie Farmaceutiche Riunite Srl, Abaxis, Inc., Accutech LLC, Alere, Inc., Biochemical Systems International Srl and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this POC Lipid Testing market report include:

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Abaxis, Inc.
  • Accutech LLC
  • Alere, Inc.
  • Biochemical Systems International Srl
  • Bio-Rad Laboratories, Inc.
  • Eurotrol B.V.
  • F. Hoffmann-La Roche AG
  • General Life Biotechnology Co., Ltd.
  • Helena Laboratories Corporation
  • Nova Biomedical Corporation

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 30 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
  • POC Lipid Testing - Global Key Competitors Percentage Market Share in 2026 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Cardiovascular Diseases Propels Market Growth
  • Advances in Point-of-Care Diagnostic Technologies Drives Adoption
  • Increasing Focus on Preventive Healthcare Expands Market Opportunities
  • Growth in Home-Based and Remote Testing Strengthens Business Case for POC Lipid Testing
  • Development of Rapid and Accurate Lipid Testing Kits Spurs Market Expansion
  • Expansion of Telemedicine and Digital Health Platforms Generates Demand
  • Increasing Awareness and Screening Programs Accelerates Market Growth
  • Enhanced Convenience and Accessibility of Modern Testing Solutions Sustains Market Demand
  • Technological Innovations in Biosensors and Microfluidics Strengthens Market Position
  • Development of Cost-Effective and Portable Testing Devices Generates Market Opportunities
  • Growth in Health and Wellness Programs Propels Market Growth
  • Increasing Demand for Comprehensive Lipid Profiling and Monitoring Sustains Market Expansion
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World POC Lipid Testing Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Instruments Offering by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Instruments Offering by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Instruments Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Consumables Offering by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Consumables Offering by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Consumables Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Lipid & Lipoprotein Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Lipid & Lipoprotein Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Lipid & Lipoprotein Disorder Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Atherosclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Atherosclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Atherosclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Liver & Renal Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Liver & Renal Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Liver & Renal Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Diabetes Mellitus Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Diabetes Mellitus Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Diabetes Mellitus Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 35: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 36: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
SPAIN
RUSSIA
REST OF EUROPE
AUSTRALIA
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
  • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Abaxis, Inc.
  • Accutech LLC
  • Alere, Inc.
  • Biochemical Systems International Srl
  • Bio-Rad Laboratories, Inc.
  • Eurotrol B.V.
  • F. Hoffmann-La Roche AG
  • General Life Biotechnology Co., Ltd.
  • Helena Laboratories Corporation
  • Nova Biomedical Corporation

Table Information